These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18398977)

  • 21. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV and sexual dysfunction.
    Colebunders R; Florence E; Schrooten W; Enzlin P
    Int J STD AIDS; 2003 Jan; 14(1):69. PubMed ID: 12590805
    [No Abstract]   [Full Text] [Related]  

  • 23. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Start anti-HIV treatment early, in adults and infants.
    Laurence J
    AIDS Read; 2009 Jan; 19(1):6-7, 17. PubMed ID: 19209449
    [No Abstract]   [Full Text] [Related]  

  • 25. Are the best antiretrovirals being used in Africa?
    John L; Kambugu A; Songa PM; Castelnuovo B; Colebunders R; Kamya M
    J HIV Ther; 2006 Mar; 11(1):11-5. PubMed ID: 16706250
    [No Abstract]   [Full Text] [Related]  

  • 26. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
    Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
    AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Chang SY; Lin SW; Hung CC
    Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
    [No Abstract]   [Full Text] [Related]  

  • 28. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
    Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
    Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute schizophrenic symptoms as the initial manifestation of HIV infection that respond to highly active antiretroviral therapy.
    Hashimoto T; Nishio M; Sakai T; Fujimoto K; Sato N; Endo T; Koike T
    Clin Infect Dis; 2006 Jun; 42(11):1653-5. PubMed ID: 16652326
    [No Abstract]   [Full Text] [Related]  

  • 30. [New therapies in the management of seropositive persons].
    Riou JM
    Soins; 2009 Apr; (734):54. PubMed ID: 19475834
    [No Abstract]   [Full Text] [Related]  

  • 31. The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study).
    Vellozzi C; Brooks JT; Bush TJ; Conley LJ; Henry K; Carpenter CC; Overton ET; Hammer J; Wood K; Holmberg SD;
    Am J Epidemiol; 2009 Mar; 169(5):642-52. PubMed ID: 19074775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
    Wilson LE; Gallant JE
    Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.
    Koyalta D; Charpentier C; Beassamda J; Rey E; Si-Mohamed A; Djemadji-Oudjeil N; Bélec L
    Clin Infect Dis; 2009 Jul; 49(1):155-9. PubMed ID: 19480574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
    Molina-Pinelo S; Vallejo A; Díaz L; Soriano-Sarabia N; Ferrando-Martínez S; Resino S; Muñoz-Fernández MA; Leal M
    J Antimicrob Chemother; 2009 Sep; 64(3):579-88. PubMed ID: 19608579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drugs for antiretroviral therapy. The costs of HAART].
    Jablonowski H
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
    [No Abstract]   [Full Text] [Related]  

  • 36. Myelodysplastic syndrome with complex karyotype associated with long-term highly active antiretroviral therapy.
    Rieg S; Lübbert M; Kern WV; Timme S; Gärtner F; Rump JA
    Br J Haematol; 2009 Jun; 145(5):670-3. PubMed ID: 19344389
    [No Abstract]   [Full Text] [Related]  

  • 37. Alterations in acute-phase proteins among HIV-1 infected persons receiving generic HAART in southern India.
    Sundaram M; Srinivas CN; Shankar EM; Balakrishnan P; Solomon S; Kumarasamy N
    J Infect; 2009 Jun; 58(6):465-7. PubMed ID: 19443037
    [No Abstract]   [Full Text] [Related]  

  • 38. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.
    Kouanfack C; Montavon C; Laurent C; Aghokeng A; Kenfack A; Bourgeois A; Koulla-Shiro S; Mpoudi-Ngole E; Peeters M; Delaporte E
    Clin Infect Dis; 2009 May; 48(9):1318-22. PubMed ID: 19320592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of HIV: a swing back to the future.
    Alozie OK; Bonham S; Henry WK
    Minn Med; 2009 Oct; 92(10):45-9. PubMed ID: 19916274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Viral loads in pediatric HIV patients with antiretroviral treatment].
    Porto-Espinoza L; Moronta R; Cuadra-Sánchez C; Callejas-Valero D; Costa-León L; Monsalve-Castillo F; Bernardoni C; Estévez J
    Rev Med Chil; 2008 Aug; 136(8):1021-6. PubMed ID: 18949186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.